<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03186989</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 814907-CS1</org_study_id>
    <nct_id>NCT03186989</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      IONIS-MAPTRx in patients with Mild Alzheimer's Disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allocation: RandomizedEndpoint Classification: Safety Study Intervention Model: Parallel
      Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2017</start_date>
  <completion_date type="Anticipated">February 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events that are related to treatment with IONIS MAPTRx</measure>
    <time_frame>Up to 253 Days</time_frame>
    <description>The safety and tolerability of ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx will be assessed by determining the incidence, severity, and dose relationship of adverse events that are related to treatment with IONIS MAPTRx</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) after ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx (trough concentration)</measure>
    <time_frame>Up to 253 days</time_frame>
    <description>The cerebrospinal fluid (CSF) trough concentrations of IONIS MAPTRx will be assessed after ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) after ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx (maximum observed drug concentration or Cmax)</measure>
    <time_frame>Up to 253 days</time_frame>
    <description>The Plasma pharmacokinetics (maximum observed drug concentration or Cmax)) of IONIS MAPTRx will be assessed after ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics after ascending dose-levels of multiple IT bolus administrations on IONIS MAPTRx (time taken to reach maximal concentration or Tmax)</measure>
    <time_frame>Up to 253 days</time_frame>
    <description>The plasma pharmacokinetics (time taken to reach maximal concentration or Tmax) of IONIS MAPTRx will be assessed following single and multiple dose IT administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics after ascending dose-levels of multiple IT bolus administrations on IONIS MAPTRx (Plasma terminal elimination half-life (t1/2λz)</measure>
    <time_frame>Up to 253 days</time_frame>
    <description>The plasma pharmacokinetics (Plasma terminal elimination half-life (t1/2λz) of IONIS-MAPTRx will be assessed following single and multiple dose IT administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics after ascending dose-levels of multiple IT bolus administrations on IONIS MAPTRx (Partial areas under the plasma concentration-time curve from zero time (predose) to selected times (t) after the IT administration (AUCt)</measure>
    <time_frame>Up to 253 days</time_frame>
    <description>The plasma pharmacokinetics (Partial areas under the plasma concentration-time curve from zero time (predose) to selected times (t) after the IT administration (AUCt) of IONIS MAPTRx will be assessed following single and multiple dose IT administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Mild Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>IONIS-MAPTRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IONIS MAPTRx (Study Drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Artificial CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS MAPTRx</intervention_name>
    <description>IONIS MAPTRx is administered intrathecally at 4 week intervals over the course of a 13 week treatment period for dose levels A, B, C, and D</description>
    <arm_group_label>IONIS-MAPTRx</arm_group_label>
    <other_name>ISIS 814907</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo is administered intrathecally at 4 week intervals over the course of 13 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged 50-74 years, inclusive, at the time of informed consent

          -  Diagnosed with mild Alzheimers disease, including CSF biomarkers consistent with this
             diagnosis

          -  Body Mass Index BMI ≥ 18 and ≤ 35 kg/m2 and total body weight &gt; 50 kg (110 lbs)

          -  Able and willing to meet all study requirements, including toleration for MRI scans,
             blood draws and lumbar punctures, travel to Study Center and participation in all
             procedures and measurements at study visits

          -  Have a trial partner who is reliable, competent and at least 18 years of age, is
             willing to accompany the patient to select trial visits and to be available to the
             Study Center by phone if needed

          -  Reside within 4 hours travel of the Study Center

        Exclusion Criteria:

          -  Treatment with another Study Drug, biological agent, or device within one-month of
             Screening or 5 half-lives of investigational agent, whichever is longer

          -  Clinically significant medical condition which would make the patient unsuitable for
             inclusion or could interfere with the patient participating in or completing the study

          -  Use of a disallowed CNS-active or antipsychotic medication within 4 weeks prior to
             Screening punctures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>800-679-4747</phone>
    <email>patients@ionisph.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montreal Neurological Hospital</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime Boutin-Caron</last_name>
      <phone>+1 514 398 5505</phone>
      <email>maxime.boutin-caron@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Angela Genge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Services Turku CRST</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Lithonius</last_name>
      <phone>358 2 4206 4712</phone>
      <email>anne.lithonius@crst.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St Josef Hospital</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Kaminski</last_name>
      <phone>49 234 5092703</phone>
      <email>b.kaminski@klinikum-bochum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Mittweida Gbr</name>
      <address>
        <city>Mittweida</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Merkel</last_name>
      <phone>+49 3727991006</phone>
      <email>merkel@mvz-mittweida.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Bodenschatz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universittsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Therese Poehler</last_name>
      <phone>+49 73150063089</phone>
      <email>therese.poehler@uni-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Christine Von Arnim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculty Medical Sciences UMCG Neurology</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Floor Morrien</last_name>
      <phone>+31 50 3048000</phone>
      <email>projectmanagement@qps.com</email>
    </contact>
    <investigator>
      <last_name>Peter P De Deyn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesmottagningen</name>
      <address>
        <city>Mölndal</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Berglund</last_name>
      <phone>+46 31 3438668</phone>
      <email>maria.a.berglund@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Anne Borjesson-Hanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann-Christine Tysen Backstrom</last_name>
      <phone>+46 8 58585468</phone>
      <email>ann-christine.tysen-backstrom@sll.se</email>
    </contact>
    <investigator>
      <last_name>Anne Borjesson-Hanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gladys Madzamba</last_name>
      <phone>+44 (0) 151 706 4860</phone>
      <email>Gladys.madzamba@rlbuht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Richard Fitzgerald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Woodgate, M.D.</last_name>
      <phone>+44 02034484531</phone>
      <email>p.woodgate@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Cath Mummery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Institute for Translational Neuroscience (SITraN)</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamel Bouakline</last_name>
      <phone>+44 01142713339</phone>
      <email>kamel.bouakline@sth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Daniel Blackburn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Alzheimer's Disease</keyword>
  <keyword>ISIS 814907</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

